Gonadal response after a single-dose stimulation test with recombinant human chorionic gonadotropin (rhCG) in patients with isolated prepubertal cryptorchidism

Carregando...
Imagem de Miniatura
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
Citação
BASIC AND CLINICAL ANDROLOGY, v.26, article ID 13, 6p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The evaluation of prepubertal gonadal Leydig cells secretion requires gonadotropin stimulation. Urinary hCG (human chorionic gonadotropin) is currently unavailable in many countries, however, recombinant hCG (rhCG) can be used. Our aim was to evaluate rhCG-stimulated testicular hormones in a group of patients with cryptorchidism. Methods: We evaluated 31 prepubertal boys (age range, 0.75-9.0 years) presenting with unilateral (n = 24) or bilateral (n = 7) cryptorchidism. Patients with other genital abnormalities, previous use of hCG or testosterone or previous surgeries were excluded. Blood samples were obtained at baseline and 7 days after a single subcutaneous dose of rhCG (Ovidrel (R) 250 mcg) to measure the testosterone, DHT (dihydrotestosterone), AMH (anti-Mullerian hormone), and inhibin B levels. Results: rhCG stimulation significantly increased testosterone levels from 10 ng/dl to 247.8 +/- 135.8 ng/dl, increased DHT levels from 4.6 +/- 0.8 to 32.3 +/- 18.0 ng/dl, and increased the T/DHT ratio from 2.2 +/- 0.4 to 8.0 +/- 3.5. There was also a significant increase in inhibin B (from 105.8 +/- 65.2 to 132.4 +/- 56.1 pg/ml; p < 0.05) and AMH levels (from 109.4 +/- 52.6 to 152.9 +/- 65.2 ng/ml; p < 0.01) after the rhCG stimulation. Conclusions: In this cohort, hormonal responses can be elicited after the rhCG stimulation test, suggesting that rhCG is a promising stimulation test to replace the urinary hCG test during the evaluation of gonadal Leydig cells function. The clinical applicability and adequate performance of rhCG testing must be investigated in future studies.
Palavras-chave
Human Chorionic Gonadotropin, Cryptorchidism, Testosterone, Anti-Mullerian hormone, Recombinant hCG
Referências
  1. Ahmed SF, 2010, CLIN ENDOCRINOL, V72, P814, DOI 10.1111/j.1365-2265.2009.03724.x
  2. Andersson AM, 1998, J CLIN ENDOCR METAB, V83, P4451, DOI 10.1210/jc.83.12.4451
  3. Botelho JC, 2013, CLIN CHEM, V59, P372, DOI 10.1373/clinchem.2012.190934
  4. Braunstein GD, 2010, ENDOCRINOLOGIA BASIC, P389
  5. Cailleux-Bounacer A, 2008, EUR J ENDOCRINOL, V159, P171, DOI 10.1530/EJE-07-0876
  6. Christiansen P, 2002, EUR J ENDOCRINOL, V147, P95, DOI 10.1530/eje.0.1470095
  7. DAVENPORT M, 1995, BRIT J UROL, V76, P790, DOI 10.1111/j.1464-410X.1995.tb00776.x
  8. Favorito Luciano A., 2005, Int. braz j urol., V31, P562, DOI 10.1590/S1677-55382005000600010
  9. FOREST MG, 1980, PEDIATR RES, V14, P819, DOI 10.1203/00006450-198006000-00009
  10. GRACIA J, 1995, BRIT J UROL, V75, P697, DOI 10.1111/j.1464-410X.1995.tb07373.x
  11. Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2
  12. LEE PA, 1980, JOHNS HOPKINS MED J, V146, P156
  13. Legro RS, 2010, J CLIN ENDOCR METAB, V95, P5305, DOI 10.1210/jc.2010-1123
  14. Longui CA, 1998, J PEDIATR ENDOCR MET, V11, P687
  15. Longui CA, 2010, MENINO MENINA DISTUR, P527
  16. Rusnack SL, 2003, J UROLOGY, V169, P659, DOI 10.1097/01.ju.0000045701.25854.f3
  17. Sidhmalswamy GSA, 2012, INT J INFERTILITY FE, V3, P92
  18. Trinchard-Lugan I, 2002, Reprod Biomed Online, V4, P106
  19. Vischer HF, 2003, MOL ENDOCRINOL, V17, P1972, DOI 10.1210/me.2003-0172